dievini Hopp BioTech holding

dievini Hopp BioTech holding is an active investor in Life and Health Sciences companies, with a focus on innovative therapeutics and diagnostics for life-threatening diseases. The firm's stated approach involves supporting portfolio-company management teams in corporate and business development, including their global development and business activities. Investment interest spans oncology, neurology, infectious diseases, cell therapy, molecular diagnostics, drug delivery systems and personalized medicine.

The firm targets what it describes as unique and first-in-class diagnostic and therapeutic approaches. In personalized medicine, its stated objective is to improve individual therapy outcomes while reducing adverse effects - a framing that positions its portfolio at the intersection of molecular diagnostics and targeted treatment. Geographic presence is anchored in Germany and Europe, with support extended to portfolio companies' activities on a global basis.

Seven portfolio companies are identified as listed: AC Immune, Cosmo Pharmaceuticals, Heidelberg Pharma, Immatics, Joimax, Molecular Health and Novaliq. The mix - spanning antibody-drug conjugates, cell and immunotherapies, ophthalmology, gastrointestinal interventions and molecular diagnostics - reflects the breadth of the firm's therapeutics and diagnostics mandate.

dievini's operating model is hands-on rather than passive: the firm works alongside management teams on corporate and business development rather than providing capital alone. No founding year, team size or fund size is disclosed publicly. Further information is available at dievini.de.